These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38046107)

  • 1. Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: Target delineation, outcomes and patterns of recurrence.
    Christ SM; Youssef G; Tanguturi SK; Cagney D; Shi D; McFaline-Figueroa JR; Chukwueke U; Lee EQ; Hertler C; Andratschke N; Weller M; Reardon DA; Haas-Kogan D; Guckenberger M; Wen PY; Rahman R
    Clin Transl Radiat Oncol; 2024 Jan; 44():100697. PubMed ID: 38046107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.
    McBain C; Lawrie TA; Rogozińska E; Kernohan A; Robinson T; Jefferies S
    Cochrane Database Syst Rev; 2021 May; 5(1):CD013579. PubMed ID: 34559423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?
    Palmer JD; Bhamidipati D; Song A; Eldredge-Hindy HB; Siglin J; Dan TD; Champ CE; Zhang I; Bar-Ad V; Kim L; Glass J; Evans JJ; Andrews DW; Werner-Wasik M; Shi W
    J Neurooncol; 2018 Dec; 140(3):623-628. PubMed ID: 30182159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab combined with re-irradiation in recurrent glioblastoma.
    She L; Su L; Liu C
    Front Oncol; 2022; 12():961014. PubMed ID: 36046037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma.
    Tsien CI; Pugh SL; Dicker AP; Raizer JJ; Matuszak MM; Lallana EC; Huang J; Algan O; Deb N; Portelance L; Villano JL; Hamm JT; Oh KS; Ali AN; Kim MM; Lindhorst SM; Mehta MP
    J Clin Oncol; 2023 Feb; 41(6):1285-1295. PubMed ID: 36260832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
    Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
    Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
    Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
    Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide.
    Hata N; Mizoguchi M; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Amemiya T; Michiwaki Y; Fujioka Y; Takigawa K; Suzuki SO; Yoshitake T; Togao O; Hiwatashi A; Yoshimoto K; Iihara K
    J Neurooncol; 2020 Feb; 146(3):451-458. PubMed ID: 32020475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temozolomide and Bevacizumab Induction before Chemoradiotherapy in Patients with Bulky Glioblastoma and/or with Severe Neurological Impairment.
    Darmon I; Morisse MC; Coutte A; Blonski M; Le Rhun E; Taillandier L; Roufai DB; Desenclos C; Trudel S; Faivre JC; Blanchard N; Chauffert B; Boone M
    J Cancer; 2017; 8(8):1417-1424. PubMed ID: 28638456
    [No Abstract]   [Full Text] [Related]  

  • 10. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
    Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re-irradiation treatment regimens for patients with recurrent glioma - Evaluation of the optimal dose and best concurrent therapy.
    Fleischmann DF; Gajdi L; Corradini S; Schönecker S; Marschner S; Bodensohn R; Hofmaier J; Garny S; Forbrig R; Thon N; Belka C; Niyazi M
    Radiother Oncol; 2024 Oct; 199():110437. PubMed ID: 39013502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial.
    Kickingereder P; Brugnara G; Hansen MB; Nowosielski M; Pflüger I; Schell M; Isensee F; Foltyn M; Neuberger U; Kessler T; Sahm F; Wick A; Heiland S; Weller M; Platten M; von Deimling A; Maier-Hein KH; Østergaard L; van den Bent MJ; Gorlia T; Wick W; Bendszus M
    Radiology; 2020 Oct; 297(1):164-175. PubMed ID: 32720870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Bevacizumab Combined with Other Therapeutic Regimens for Treatment of Recurrent Glioblastoma: A Network Meta-analysis.
    Dongpo S; Zhengyao Z; Xiaozhuo L; Qing W; Mingming F; Fengqun M; Mei L; Qian H; Tong C
    World Neurosurg; 2022 Apr; 160():e61-e79. PubMed ID: 34973444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme.
    Shields LB; Kadner R; Vitaz TW; Spalding AC
    Radiat Oncol; 2013 Apr; 8():101. PubMed ID: 23618500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re-irradiation after gross total resection of recurrent glioblastoma : Spatial pattern of recurrence and a review of the literature as a basis for target volume definition.
    Straube C; Elpula G; Gempt J; Gerhardt J; Bette S; Zimmer C; Schmidt-Graf F; Meyer B; Combs SE
    Strahlenther Onkol; 2017 Nov; 193(11):897-909. PubMed ID: 28616821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) - protocol of a randomized phase II trial (NOA 10/ARO 2013-1).
    Oehlke O; Mix M; Graf E; Schimek-Jasch T; Nestle U; Götz I; Schneider-Fuchs S; Weyerbrock A; Mader I; Baumert BG; Short SC; Meyer PT; Weber WA; Grosu AL
    BMC Cancer; 2016 Oct; 16(1):769. PubMed ID: 27716184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
    Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
    J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes of dose-escalated re-irradiation in patients with recurrent high-grade glioma.
    Helis CA; Prim SN; Cramer CK; Strowd R; Lesser GJ; White JJ; Tatter SB; Laxton AW; Whitlow C; Lo HW; Debinski W; Ververs JD; Black PJ; Chan MD
    Neurooncol Pract; 2022 Oct; 9(5):390-401. PubMed ID: 36134018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes.
    Bovi JA; Prah MA; Retzlaff AA; Schmainda KM; Connelly JM; Rand SD; Marszalkowski CS; Mueller WM; Siker ML; Schultz CJ
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):979-986. PubMed ID: 32599030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.